Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

NCT05982834 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Gastric Cancer
Immunotherapy

Interventions

DRUG: Disitamab Vedotin combined with fruquintinib and Tislelizumab

Sponsor

Fudan University